Compare AbbVie Inc (ABBV) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs MPLX LP — how do they compare? AbbVie Inc trades at $253.88 (market cap $449.91B), while MPLX LP trades at $57.05 (market cap $58.36B). The key difference: AbbVie Inc is far larger — about 7.7× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.49%). Which is the better fit depends on your goals.
| ABBV | MPLX | |
|---|---|---|
Market Cap | $449.91B | $58.36B |
Sector | Health | Technology |
52-Week High | $261.07 | $59.17 |
52-Week Low | $184.85 | $47.80 |
Enterprise Value | $513.38B | $82.99B |
Dividend Yield | 2.72% | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
MPLX trades at $56.97, down 0.33% on the day, with a bullish technical signal supported by moving averages and key indicators like ADX. Financially, the company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 2026 EPS missed expectations. Analyst consensus is strongly positive with a $60.60 price target, and the recent $1.08 dividend underscores its income appeal.
The outlook for MPLX remains favorable, driven by its high-yield dividend, stable cash flows from fee-based contracts, and strategic focus on natural gas and NGL services. Key risks include exposure to energy commodity volatility and high debt levels. Upside potential hinges on execution of growth projects and sustained distribution growth amid a supportive midstream environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
